Astragaloside IV
Catalog No: CFN99171
Astragaloside IV can protect the myocardium against ischemia/reperfusion injury, inhibit adenovirus replication and apoptosis in A549 cells in vitro, has anti-fibrotic effect against systemic sclerosis, and may be useful in ameliorating food-induced metabolic syndrome and membranous nephropathy. It suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.
Salidroside
Catalog No: CFN99177
Salidroside is a prolyl endopeptidase inhibitor, which has cardioprotective, antidiabetic,antidepressant, anxiolytic, anti-tumor, and antioxidant actions. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. It alleviates the pulmonary symptoms of paraquat-induced acute lung injury, at least partially, by repressing inflammatory cell infiltration and the expression of TGF-β1 resulting in delayed lung fibrosis; and it has protective effect against hypoxia-induced cardiomyocytes necrosis and apoptosis by increasing HIF-1α expression and subsequently up-regulating VEGF levels. It may be a potential therapeutic agent for treating or preventing neurodegenerative diseases implicated with oxidative stress.
Sophocarpine
Catalog No: CFN99182
Sophocarpine has anti-cachectic, anti-inflammatory, and neuroprotective effects. It has significant antivirus effects against coxsackievirus B3 and therapeutic effects for viral myocarditis in clinical, can ameliorate the ischemic injury induced by transient focal cerebral ischemia in rats, and may be a potential chemotherapeutic agent for chronic liver diseases. Sophocarpine inhibited the expression of TNF-alpha, IL-6, JNK, iNOS, COX-2, p38 MAPK, NF-κB, TLR4, and activated signaling pathway of AMPK.